Exclusive Summary

• Differentiated Anti-IL-6R mAb with Best-in-Class Potential: Integrates a unique pH-dependent binding mechanism reducing intracellular degradation, delivering hundreds-fold higher target affinity and 20-30 times greater activity than Tocilizumab.
• Overwhelming Efficacy in Life-threatening iMCD: Demonstrates an ultra-rapid onset of action (14-42 days) and an 80-90% symptomatic response rate, perfectly solving the 66% non-response failure rate of current SoC Siltuximab.
• Flawless Safety Profile and Long Commercial Lifespan: Achieved a 0% SAE rate in clinical trials and secured robust global patent protection (including US, EU, JP) with a PCT validity extending to 2037.
• Exceptional Licensing and Accelerated Regulatory Value: With completely differentiated data in a high-mortality rare disease, it holds massive potential for FDA/EMA Orphan Drug Designations (ODD) and breakthrough therapy pathways, making it highly attractive for out-licensing.

Asset Materials

Contact Us for Full Materials